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ibbyetal.(1),inthisissueofDiabetes
Care, report a lower incidence of a
broad range of cancers among dia-
betic patients treated with metformin.
Speciﬁcally, by linking data from a popu-
lation-based diabetes registry with those
from a drug use registry and a cancer reg-
istry,theyeffectivelyfollowedmedication
useinover8,000diabeticindividualsand
ascertained over 700 incident cancers.
They found, over a 10-year period, that
metformin use was associated with a 54%
(95% CI 47–60) lower crude and a 37%
(25–47) lower adjusted incidence of can-
cer. From the survival analysis they per-
formed adjusting for age, sex, BMI,
smoking status, and a social deprivation
index, one can estimate the association in
absolute terms: considering the cancer
rate of 11.6% for non–metformin users,
for every 23 patients receiving metformin
inthiscohortonefewerdevelopedcancer
(number needed to treat  1/[0.37 
0.116]).Theirﬁndingsareinternallycon-
sistent. In patients with the longest his-
tory of metformin use prior to cancer
onset,incidencetendedtobelowest.Met-
formin users who developed cancer also
had a greater survival postdiagnosis. A
protective association of similar degree
wasdocumentedagainstlung,bowel,and
breast cancer.
Because these ﬁndings come from a
large cohort study constructed with
record linkage rather than from a ran-
domized clinical trial, they require trial
conﬁrmation prior to clinical application.
Nevertheless, they add to a rapidly grow-
ing literature suggesting, on the basis of a
plausible mechanism and consistent em-
piricalﬁndingsinbothlaboratoryanimals
and humans, that metformin not only ex-
erts a major protective effect against the
development of a wide range of cancers
but also improves prognosis in those
found to have these cancers.
In addition to a preliminary report
based on the same diabetes registry (2),
the ﬁndings of three other studies are in
consonance with that of Libby et al.
Bowker et al. (3) performed a cohort
study with record linkage involving
12,272 new oral antidiabetes drug users
in the Saskatchewan provincial health
system from 1991 to 1996. Over a mean
follow-up of 5.4 years, sulfonylurea users
had adjusted cancer mortality 30%
greater than that for metformin users (HR
1.3 [95% CI 1.1–1.6]) and insulin users
an adjusted cancer mortality 90% greater
(1.9 [1.5–2.4]). Monami et al. (4), in a
case-control study comparing 195 inci-
dent cancer cases with 195 matched con-
trol subjects nested within the follow-up
of consecutive diabetic patients attending
an Italian university-afﬁliated outpatient
clinic, found odds of 0.28 (0.13 – 0.57)
for developing cancer in those with 36
months of metformin use. In a hospital-
based case-control study of pancreatic
cancer that included 350 diabetic pa-
tients,Lietal.(5)foundthatamongthose
with diabetes, users of metformin had ad-
justed odds of 0.38 (0.22–0.69) of devel-
oping cancer compared with those never
using metformin, whereas users of insu-
lin, insulin secretagogues, and glitazones
all had increased risk compared with
those who never used these drugs.
In terms of cancer prognosis, Jiraler-
spong et al. (6) reported that among dia-
betic breast cancer patients receiving
neoadjuvant chemotherapy, those who
wereincidentallyreceivingmetforminex-
periencedapathologiccompleteresponse
rate of 24% as opposed to only 8% for
those not receiving the drug (P  0.001).
In fact, ﬁndings such as these have re-
cently led to the development of at least
three clinical trials aiming to evaluate
metformin as adjuvant therapy in the
treatment of cancer (7,8).
In the context of these previous stud-
ies, Libby et al., given the size and meth-
odologic quality of the study, provide us
with a major step forward in the charac-
terizationofthemetformin-cancerassoci-
ation and its potential in terms of both
reducing risk and improving prognosis of
cancer. Certainly other studies will follow
that will help estimate where in fact the
association’spointestimatesliewithinthe
CIs Libby et al. present.
Why should a diabetes drug be pro-
tective against cancer? A review of met-
formin’s principal mechanism of action,
through AMP-activated protein kinase
(AMPK), provides at least one plausible
answer. AMPK is one of those fascinating
orchestrators of our inner workings that
have emerged from the battlegrounds of
evolution. Molecules similar to mamma-
lianAMPKcanbefoundnotjustthrough-
out the animal kingdom but also in
plants, protists, and fungi (9), and evolv-
ingformsofAMPKhaveaccompaniedthe
evolution of higher organisms.
The language of life is composed of
many such chemical signals (10), each
talking to the others in tongues that little
by little we in the scientiﬁc community
have come to understand. This language
evolved through a long series of itera-
tions,advancesineachbeingbasedonthe
building blocks at that time present, with
molecules frequently being borrowed
from their original roles and adapted to
performnewones.Giventheresultantre-
dundancy and nonspeciﬁcity of the sys-
tems that emerged, we should not be
surprised to ﬁnd that a molecule with a
major role in metabolism and diabetes
mightalsobeakeyactorintheetiologyof
cancer.
Better understanding of these signals
and their pathways and our ability to
place the mechanisms underlying clinical
events such as diabetes or cancer within
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among the scientiﬁc challenges of our
day.Thepathophysiologyofmajorkillers
such as diabetes, cardiovascular disease,
and cancer lies nested within this frame-
work. The characterization of these dis-
eases as degenerative implies a process of
wear and tear, a by-product of the normal
workings of the life span. Etiologically, it
may be more interesting to characterize
them with a different focus, as being the
direct product of aberrant signaling—the
right signals but at the wrong time or
place—as the human body reacts in its
time-honoredfashiontochallengesthatit
was not selected to meet.
Intheage-longstruggleforsurvivalof
species, AMPK early on assumed the role
of energy quartermaster—its task to reg-
ulate energy supply and utilization to
maintain health. Taking stock of intracel-
lular nutrient stores, AMPK acts to con-
servecurrentandgeneratenewATP.Inso
doing, when necessary, it signals restraint
in ATP-expending chores like gluconeo-
genesis, orders the transformation of in-
tracellular fats and carbohydrates into
ATP, and stimulates the uptake of new
energy from extracellular sources. In
terms of diabetes, this makes it a “good
guy,”loweringhepaticglucoseoutput,in-
creasing glucose uptake, maintaining in-
sulin sensitivity, and as a result lowering
plasma glucose levels (9). As more elabo-
ratelifeformsevolved,AMPKtookonad-
ditional tasks. In terms of cancer, its
basically antianabolic/procatabolic role
appears to have become a pathway
throughwhichnaturaltumorsuppressors
signal the shutdown, or at least slow
down, of aberrant cellular growth (11).
The lower risk of cancer with met-
forminusereportedbyLibbyetal.should
be viewed within the context of the
greaterriskofcancerassociatedbothwith
diabetesandwithobesity.Withrespectto
diabetes, Barone et al. (12), in a meta-
analysis of 23 population- and clinic-
based observational studies, found an
overall HR for all cancer types of 1.41
(95%CI1.28–1.55)forthosewithdiabe-
tes when compared with normoglycemic
individuals.Thoughpowerwaslimitedto
testassociationswithspeciﬁccancers,ep-
idemiologically signiﬁcant positive asso-
ciations were found for a broad range of
cancers including endometrial, breast,
prostate, gastric, colorectal, and hepato-
cellular. Hyperglycemia, in other studies,
has additionally been predictive of mela-
noma and cancers of the kidney and pan-
creas (8).
Why should diabetes predict greater
cancer risk? Is it disease treatment or
something related inherently to the dis-
ease?Somestudiesnowsuggestthatinsu-
lin and insulin secretagogue use increases
cancer risk (3,5). Higher C-peptide and
insulin levels have predicted cancer in
some studies, and because insulin stimu-
latesgrowth,apathophysiologicrationale
exists for the risk seen with these treat-
ments (8).
On the other hand, some of the dia-
betes-cancer association could be ex-
plained through confounding by obesity.
Mostofthestudiesinthemeta-analysisby
Barone et al. were not adjusted for obe-
sity, and in another recent meta-analysis
byRenehanetal.(13),obesitywasshown
to increase cancer risk for more than a
dozen different cancers, with highest risk
(relative risks 1.17 to 1.59 for a 5-unit
difference in BMI) for endometrial,
esophageal (adenocarcinoma), gall blad-
der, thyroid, colorectal, liver, pancreatic,
and kidney cancers. However, because
several studies summarized in the meta-
analysis by Barone et al. showed diabetes-
cancer associations even after control for
adiposity, confounding by obesity is
probably only a part of the explanation.
Obesitylowersadiponectinlevelsand
leadstoleptinresistance.Diabetesisadis-
ease preceded and accompanied by lower
levelsofadiponectin(14)andlowereffec-
tive levels of leptin (15). Both of these
molecules have been shown to act, in
part, by activating AMPK. A limited num-
berofstudieshaveinvestigatedadiponec-
tin levels as predictors of cancer. About
half show decreased risk estimates of a
size that could be considered epidemio-
logically important (8).
Because AMPK is activated by low in-
tracellular energy stores, could weight
loss be an additional clinically relevant
trigger? Observational studies investigat-
ing weight loss and subsequent cancer
provide mixed results, perhaps in large
part because of the potential for reverse
causality given that cancer causes weight
loss. Thus, the recent report of a nonran-
domizedcontrolledtrialbySjo ¨stro ¨metal.
(16) on the effect of bariatric surgery on
cancer risk in 4,047 obese subjects is of
great interest. Bariatric surgery patients
had a sustained weight reduction 18.6 kg
greaterthancontrolsubjectsover10years
of follow-up. A major reduction in cancer
incidence with bariatric surgery was
foundinwomen(HR0.58[95%CI0.44–
0.77]) but not men (0.97 [0.26 – 1.52]).
As related by Renehan (17) in an accom-
panying editorial, retrospective analyses
of investigations of bariatric surgery out-
comesbyafewothergroupssupportboth
the effect seen in women and the absence
of such an effect in men.
The amount of weight change during
the ﬁrst year of follow-up, analyzed sepa-
rately in bariatric surgery and control
groups, was not related to cancer risk
from the fourth year onward in the study
of Sjo ¨stro ¨m et al. This association, how-
ever, is an observational one, and weight
loss from latent cancer might be present
in spite of the exclusion of early cancers.
Physical activity has also been shown
to be a strong activator of AMPK (18).
Meta-analyses of observational studies
suggest that higher levels of physical ac-
tivity protect against cancers such as lung
and colon. For lung cancer, the summary
adjusted odds ratios were 0.87 (95% CI
0.79–0.95) for moderate leisure-time
physicalactivityand0.70(0.62–0.79)for
high activity (19). For colon cancer, the
summary relative risk was 0.79 (95% CI
0.72–0.87) for greater recreational activ-
ity for men and 0.71 (0.57–0.88) for
women (20).
The role of epidemiology in uncover-
ing the etiology of disease has evolved
over the years. Few are the opportunities
for epidemiologists, nowadays, to raise
newhypothesessuchasthosewhichJohn
Snow proposed for cholera and Ignaz
Semmelweis for puerperal fever. More
frequently,inquestionssuchasthosethat
populate the diabetes journals, ours is the
role of validating ﬁndings emerging from
bench research. In this role, epidemiolo-
gists help the scientiﬁc community to
identify ﬁndings of potential clinical and
epidemiologic relevance from within the
alphabetsoupofmoleculesandpathways
reported as important in bench research.
In this manner, ﬁndings of Libby et al.
highlight the potential protective func-
tion for AMPK in cancer etiology and the
potential role for metformin, our current
means of enhancing AMPK activity, in
cancer prevention.
In regards to clinical trials, a logical
place to start would be investigating can-
cer outcomes in large, already completed
metformin trials such as the United King-
dom Prospective Diabetes Study and the
Diabetes Prevention Program. Regarding
a better understanding of AMPK and its
regulation, both in terms of diabetes and
of cancer, better comprehension of the
components of the language of life and
their responses to today’s environmental
stimuli provide the groundwork not only
Duncan and Schmidt
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more effective options for a healthy life-
style and for societal health promotion.
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